Ofatumumab (Arzerra)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:41, 13 May 2012 by Dryang (talk | contribs) (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

Also known as HuMax-CD20.

General information

Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20 molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC).[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Ofatumumab (Arzerra) package insert
  2. ↑ Ofatumumab (Arzerra) package insert (locally hosted backup)
  3. ↑ Ofatumumab (Arzerra) patient drug information (Chemocare)
  4. ↑ Ofatumumab (Arzerra) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Ofatumumab_(Arzerra)&oldid=1493"